Drugs / RB-ADSC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07373067 | Jan 2026 → Jan 2028 expected | Alzheimer disease | Regeneration Biomedical, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05667649 | Aug 2023 → Aug 2026 overdue | Alzheimer disease | Regeneration Biomedical, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07205601 | Nov 2025 → Mar 2028 expected | Alzheimer disease | Regeneration Biomedical, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RB ADSC | “RB ADSC consists of stem cells obtained from the participant's own adipose tissue by lipoaspirate that have been cultured and expanded outside the body, enriched for...” NCT07205601 ↗ |
| Modality | Cell therapy | “Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)” NCT05667649 ↗ |
| Route | Other | “Intracerebroventricular Injections” NCT05667649 ↗ |